Clinical trials: Hepatitis A
Alcoholic Hepatitis (AH)
Recompensation in Alcohol Related Hepatitis
Genetic activity and metabolic changes may be part of the pathogenesis in alcohol related hepatitis. We do not know exactly how alcohol cessation affects liver functions and metabolism.
- Trial name
- A-HEP (NCT06740318)
- Testing
- Motivational enhancement therapy
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Nina Kimer
Hepatitis C, Chronic
Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C
This study aimed to evaluate the safety and efficacy of KW-136, an investigational anti-hepatitis C virus (HCV) drug, combined with sofosbuvir for treatment of Chinese adults chronically infected with HCV.
- Trial name
- KW-136_II (NCT03416491)
- Testing
- KW-136, Sofosbuvir
- Where
- 12 sites in China
- Volunteers
- 110 people
- Sponsor
- Kawin Technology Share-holding Co., Ltd.
Hepatitis A
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
Infants born to immune mothers and therefore having passively-transferred maternal antibody (PMA) to hepatitis A virus (HAV) have a blunted immune response to hepatitis A vaccine.
- Trial name
- NCT00139113
- Testing
- hepatitis A vaccine
- Where
- 2 sites in United States
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Hepatitis C, Smoking Cessation
HCV-Smoking Cessation Study
A 12-week study for patients who are being treated for Hepatitis C and would like to quit smoking. During the 12 weeks of Hepatitis C treatment, the research team will have counseling sessions with the participants to discuss…
- Trial name
- NCT05466981
- Testing
- Cognitive Behavioral Counseling
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Prisma Health-Upstate
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Inflammatory Bowel Diseases, Hepatitis B
Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients
Inflammatory bowel disease (IBD) has witnessed a rising incidence globally and in Hong Kong, an area where chronic hepatitis B (CHB) remains endemic.
- Trial name
- NCT04083157
- Testing
- Intradermal hepatitis B vaccine with imiquimod, Intramuscular hepatitis B vaccine with aqueous cream
- Where
- China
- Volunteers
- 104 people
- Sponsor
- The University of Hong Kong
Chronic Hepatitis C
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Treatment with peginterferon plus daily low dose (800 mg) or weight-based ribavirin (800-1400 mg) for 24 to 48 weeks has achieved 70-93% sustained virologic response (SVR) rates in patients with genotype 2 or 3 chronic hepatitis…
- Trial name
- NCT00532701
- Testing
- Peg-IFN + WB RBV for 16 weeks, Peg-IFN + LD RBV for 16 weeks, Peg-IFN + WB RBV for 24 weeks
- Where
- 9 sites in Taiwan
- Volunteers
- 880 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis B
Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers
Prevention of perinatal transmission is essential to decrease the global burden of chronic HBV. Recombinant HBV vaccine and hepatitis B immunoglobulin (HBIG) given after delivery to the newborns of HBsAg positive mothers is the…
- Trial name
- NCT01412567
- Testing
- Vaccine+HBIG
- Where
- India
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Govind Ballabh Pant Hospital
Chronic Hepatitis C
Pharmacogenomic Research in Korean Patients With Hepatitis C
The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV).
- Trial name
- NCT01453244
- Where
- South Korea
- Volunteers
- 373 people
- Sponsor
- Inje University
Hepatitis C Virus
TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light
The purpose of the study is to evaluate the potential effect of TMC435 on the sensitivity of the skin towards exposure to sunlight.
- Trial name
- NCT01124799
- Testing
- TMC435, Ciprofloxacin
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C Virus Infection, Infection
Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C
This trial is to determine the safety of valacyclovir in persons with chronic hepatitis C and herpes simplex type 2 infection. Participants will be randomized to valacyclovir or matching placebo.
- Conditions
- Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
- Trial name
- NCT01037621
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- G.V. (Sonny) Montgomery VA Medical Center
Hepatocellular Carcinoma, Hepatitis C
Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response
In this international collaboration study, the research group will analyze somatic mutations of hepatocellular carcinoma (HCC) developed after sustained virological response (SVR) in patients treated with hepatitis C (HCV) therapy
- Trial name
- HEPCASUS (NCT03254121)
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Karolinska Institutet
Hepatitis A, Hep A
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs
The purpose of this study is to evaluate immunogenicity and safety of inactivated hepatitis A vaccine in healthy children aged from 24 months to 15 years when administered an initial dose followed by a booster dose (a total of 2…
- Trial name
- NCT05613127
- Testing
- Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL, HAVRIX 720 Junior 0.5 mL
- Where
- 2 sites in South Korea, Thailand
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Boryung Biopharma Co., Ltd.
Chronic Hepatitis C
Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)
This observational study will examine the efficacy and safety of pegylated interferon (peginterferon) alfa-2a, mostly in combination with ribavirin treatment in chronic hepatitis C (CHC). Quality of care will also be assessed.
- Trial name
- NCT02106156
- Testing
- Pegylated interferon alfa-2a, Ribavirin
- Where
- Germany
- Volunteers
- 10,228 people
- Sponsor
- Hoffmann-La Roche
Healthy, Healthy Adult
Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program
This study is a cross-sectional study. The study aims to determine the levels of immunity against hepatitis B virus and varicella-zoster virus in medical students.
- Trial name
- NCT06901362
- Where
- Thailand
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Thammasat University
Chronic Hepatitis C
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both…
- Trial name
- INSIGHT (NCT01513941)
- Testing
- Telaprevir, Ribavirin, Pegylated-Interferon-alfa-2a
- Where
- 31 sites in Australia, Brazil and 6 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV
Hepatitis, Tuberculosis
Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment
Hepatitis during anti-tuberculous treatment (HATT) has been an obstacle in managing TB patients, especially in those with viral hepatitis.
- Conditions
- Hepatitis, Tuberculosis, hepatitisB
- Trial name
- HBV (NCT01724723)
- Testing
- entecavir (BARACLUDE®)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Chronic Liver Disease
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death.
- Trial name
- FALL (NCT05335603)
- Where
- Denmark
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
HBV, Fibrosis, Liver
Chronic Hepatitis B Virus Infection in Zambia
Chronic hepatitis B virus infection is a common condition in Zambia. Among Zambian blood donors, up to 8% are chronically infected with HBV.
- Conditions
- HBV, Fibrosis, Liver, Cirrhosis, Liver, Alcoholic Hepatitis
- Trial name
- HUTCH (NCT03158818)
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 326 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis C
Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4
Genotype 4 is the least-studied hepatitis C virus genotype and was considered a difficult to treat genotype due to the disappointing response of chronic hepatitis C genotype 4 to conventional interferon monotherapy.
- Trial name
- NCT00277862
- Testing
- Pegylated IFN- alpha 2b, Ribavirin
- Where
- 4 sites in Egypt
- Volunteers
- 280 people
- Sponsor
- Ain Shams University